BVF INC/IL recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
C/o Grosvenor Capital Management Chicago, IL 60611
As of the latest 13F report, the guru’s equity portfolio contained 78 stocks valued at a total of $2.37Bil. The top holdings were MLTX(9.64%), AXSM(5.71%), and RPTX(5.15%).
According to GuruFocus data, these were BVF INC/IL’s top five trades of the quarter.
Axsome Therapeutics Inc
The guru established a new position worth 1,755,000 shares in NAS:AXSM, giving the stock a 5.71% weight in the equity portfolio. Shares traded for an average price of $59.77 during the quarter.
On 02/18/2023, Axsome Therapeutics Inc traded for a price of $66.62 per share and a market cap of $2.89Bil. The stock has returned 119.07% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Axsome Therapeutics Inc has a price-book ratio of 18.40, a EV-to-Ebitda ratio of -17.81 and a price-sales ratio of 102.61.
Ionis Pharmaceuticals Inc
BVF INC/IL reduced their investment in NAS:IONS by 1,751,144 shares. The trade had a 3.2% impact on the equity portfolio. During the quarter, the stock traded for an average price of $42.06.
On 02/18/2023, Ionis Pharmaceuticals Inc traded for a price of $38.6 per share and a market cap of $5.48Bil. The stock has returned 17.90% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 4 out of 10.
In terms of valuation, Ionis Pharmaceuticals Inc has a price-book ratio of 9.21, a EV-to-Ebitda ratio of 135.27 and a price-sales ratio of 6.24.
The price-to-GF Value ratio is 1.29, earning the stock a GF Value rank of 1.
Relmada Therapeutics Inc
The guru sold out of their 2,078,220-share investment in NAS:RLMD. Previously, the stock had a 3.18% weight in the equity portfolio. Shares traded for an average price of $8.779999999999999 during the quarter.
On 02/18/2023, Relmada Therapeutics Inc traded for a price of $3.67 per share and a market cap of $110.46Mil. The stock has returned -80.36% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Relmada Therapeutics Inc has a price-book ratio of 0.63 and a EV-to-Ebitda ratio of 0.49.
Zymeworks Inc
The guru established a new position worth 5,870,000 shares in NAS:ZYME, giving the stock a 1.95% weight in the equity portfolio. Shares traded for an average price of $7.03 during the quarter.
On 02/18/2023, Zymeworks Inc traded for a price of $8.619999999999999 per share and a market cap of $543.09Mil. The stock has returned 22.10% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Zymeworks Inc has a price-book ratio of 2.96, a EV-to-Ebitda ratio of -1.86 and a price-sales ratio of 16.16.
The price-to-GF Value ratio is 0.04, earning the stock a GF Value rank of 2.
Immunovant Inc
The guru established a new position worth 2,561,000 shares in NAS:IMVT, giving the stock a 1.92% weight in the equity portfolio. Shares traded for an average price of $12.59 during the quarter.
On 02/18/2023, Immunovant Inc traded for a price of $18.34 per share and a market cap of $2.39Bil. The stock has returned 232.85% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Immunovant Inc has a price-book ratio of 5.71 and a EV-to-Ebitda ratio of -9.94.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
